# A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

> **NCT05567887** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 7 (actual)

## Conditions studied

- Lymphoma
- Multiple Myeloma

## Interventions

- **DRUG:** maplirpacept (PF-07901801)

## Key facts

- **NCT ID:** NCT05567887
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-02
- **Primary completion:** 2024-10-02
- **Final completion:** 2024-10-02
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05567887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05567887, "A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05567887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*